Home/Pipeline/LB-02

LB-02

Presbyopia

DiscoveryActive

Key Facts

Indication

Presbyopia

Phase

Discovery

Status

Active

Company

Lento Bio

About Lento Bio

Lento Bio is pioneering a disease-modifying therapeutic approach for presbyopia, the universal age-related loss of near vision affecting over 1.8 billion people. Its lead candidate, LB-01, is a small molecule prodrug eye drop designed to cleave disulfide crosslinks in the lens, restoring flexibility and accommodation. The company is in the discovery/IND-enabling stage, with compelling preclinical data showing significant rejuvenation of lens flexibility in models. Lento Bio operates in a massive, underserved market with no approved disease-modifying treatments, positioning it as a potential disruptor in ophthalmology and aging biology.

View full company profile

Therapeutic Areas

Ophthalmology Age-Related Disorders

Other Presbyopia Drugs

Drug	Company	Phase	Status
Presbyopia Treatment	Viatris (2)	NDA Submitted	Active
Presbyopia-Correcting ICL	STAAR Surgical	Research & Development	Active R&D
LB-01	Lento Bio	Discovery/IND-Enabling	Active
Presbyopia-Correcting Contact Lenses	Clerio Vision	Development	Active
Intra-corneal Implant	MAG Optics	Pre-clinical	Active
NVK029	Vyluma	Phase 2	Active
ArtiPlus	Ophtec	Clinical Trials	Active
BRIMOCHOL™ PF	Tenpoint Therapeutics	NDA Submitted	Active
Qlosi™	Orasis Pharmaceuticals	Approved	Active
TSH‑001	TSH Biopharm	Phase 1/2	Active
DE-128A	Santen Pharmaceutical	Phase 2	Active
YP-10	Viatris	NDA Filed	Under FDA Review (PDUFA date set)